NASDAQ:ATRS - Antares Pharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.12 -0.19 (-5.74 %)
(As of 03/24/2019 01:39 AM ET)
Previous Close$3.12
Today's Range$3.11 - $3.34
52-Week Range$1.99 - $3.96
Volume1.28 million shs
Average Volume1.60 million shs
Market Capitalization$500.85 million
P/E Ratio-78.00
Dividend YieldN/A
Beta1.15
Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector II needle-free auto injectors to administer human growth hormone for patients with growth retardation; and VIBEX disposable pressure-assisted auto injectors. In addition, the company develops XYOSTED for the treatment of testosterone deficiency in adult males; VIBEX auto injectors for treating anaphylaxis; and disposable pen injectors for diabetes and osteoporosis. It has strategic alliances with Teva Pharmaceutical Industries, Ltd. and AMAG Pharmaceuticals, Inc., as well as a development agreement with Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.

Receive ATRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ATRS
CUSIP03664210
Phone609-359-3020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$63.55 million
Book Value$0.25 per share

Profitability

Net Income$-6,510,000.00

Miscellaneous

EmployeesN/A
Market Cap$500.85 million
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable

Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

How were Antares Pharma's earnings last quarter?

Antares Pharma Inc (NASDAQ:ATRS) announced its quarterly earnings results on Thursday, February, 28th. The specialty pharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.03) by $0.07. Antares Pharma had a negative return on equity of 22.42% and a negative net margin of 10.25%. View Antares Pharma's Earnings History.

When is Antares Pharma's next earnings date?

Antares Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Antares Pharma.

What guidance has Antares Pharma issued on next quarter's earnings?

Antares Pharma updated its FY 2019 earnings guidance on Thursday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $95-105 million, compared to the consensus revenue estimate of $104.88 million.

What price target have analysts set for ATRS?

5 analysts have issued 1-year price targets for Antares Pharma's shares. Their forecasts range from $1.99 to $8.00. On average, they expect Antares Pharma's stock price to reach $4.8280 in the next year. This suggests a possible upside of 54.7% from the stock's current price. View Analyst Price Targets for Antares Pharma.

What is the consensus analysts' recommendation for Antares Pharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Antares Pharma.

Has Antares Pharma been receiving favorable news coverage?

Media headlines about ATRS stock have trended somewhat negative on Sunday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Antares Pharma earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave press coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term.

Who are some of Antares Pharma's key competitors?

What other stocks do shareholders of Antares Pharma own?

Who are Antares Pharma's key executives?

Antares Pharma's management team includes the folowing people:
  • Mr. Robert F. Apple, CEO, Pres & Director (Age 53)
  • Mr. Fred M. Powell, Exec. VP & CFO (Age 58)
  • Mr. Peter J. Graham, Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 52)
  • Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 56)
  • Edward Kessig, VP of Sales

Who are Antares Pharma's major shareholders?

Antares Pharma's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.50%), FMR LLC (2.24%), Broadfin Capital LLC (2.19%), Sargent Investment Group LLC (1.97%), Mycio Wealth Partners LLC (1.20%) and Northern Trust Corp (1.11%). Company insiders that own Antares Pharma stock include Fred M Powell, Jacques Gonella, Leonard S Jacob, Robert F Apple and Thomas J Garrity. View Institutional Ownership Trends for Antares Pharma.

Which major investors are selling Antares Pharma stock?

ATRS stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Mycio Wealth Partners LLC, Falcon Point Capital LLC, Barclays PLC, FMR LLC, Advisor Group Inc., MetLife Investment Advisors LLC and IFP Advisors Inc. Company insiders that have sold Antares Pharma company stock in the last year include Jacques Gonella and Robert F Apple. View Insider Buying and Selling for Antares Pharma.

Which major investors are buying Antares Pharma stock?

ATRS stock was purchased by a variety of institutional investors in the last quarter, including Sargent Investment Group LLC, Millennium Management LLC, Fosun International Ltd, Essex Investment Management Co. LLC, Two Sigma Investments LP, BlackRock Inc., Two Sigma Advisers LP and Geode Capital Management LLC. View Insider Buying and Selling for Antares Pharma.

How do I buy shares of Antares Pharma?

Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Antares Pharma's stock price today?

One share of ATRS stock can currently be purchased for approximately $3.12.

How big of a company is Antares Pharma?

Antares Pharma has a market capitalization of $500.85 million and generates $63.55 million in revenue each year. The specialty pharmaceutical company earns $-6,510,000.00 in net income (profit) each year or ($0.04) on an earnings per share basis.

What is Antares Pharma's official website?

The official website for Antares Pharma is http://www.antarespharma.com.

How can I contact Antares Pharma?

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]


MarketBeat Community Rating for Antares Pharma (NASDAQ ATRS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  310 (Vote Outperform)
Underperform Votes:  226 (Vote Underperform)
Total Votes:  536
MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote "Outperform" if you believe ATRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/24/2019 by MarketBeat.com Staff

Featured Article: Derivative

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel